Prospects for New Cannabis-Based Prescription Medicines

Whittle, B. A.; Guy, Geoffrey W.; Robson, Philip

doi:10.1300/j175v01n03_12

Cited by 43 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As previously published two years ago (Whittle, Guy, and Robson 2001), many hurdles exist when considering the concept of how to produce a prescription cannabis product (p. 186):…”

mentioning

confidence: 99%

“…Drying under a stream of dehumidified air from 25 down to 12% moisture content is then achieved under dark conditions to minimize cannabinoid oxidation (Whittle, Guy, and Robson 2001). The resultant mixture of dried unfertilized flowers, stalks and leaves yields 15% THC or 8% CBD in the respective chemovars (Figures 3,4,and 5).…”

mentioning

confidence: 99%

“…Historically, cannabis extracts were ethanol-based, dating back to the experiments of O'Shaughnessy in India in the 19th century (O'Shaughnessy 1838-1840). GW Pharmaceuticals has opted for a more modern technique employing supercritical CO 2 extraction (Whittle, Guy, and Robson 2001). This has distinct advantages, as organic materials are extracted at approximately body temperature with retention of essential oil terpenoid components that seemingly contribute to medicinal effects of cannabis (McPartland and Russo 2001).…”

mentioning

confidence: 99%

“…Inhaled, non-smoked delivery of isolated THC has been previously investigated (Tashkin et al 1977), but curiously, the isolated molecule is quite irritating to the bronchioles and induces a cough reflex despite its notable bronchodilatory benefits (Williams, Hartley, and Graham 1976). Biophysical parameters for this method of delivery are exacting, and have been recently reviewed (Whittle, Guy, and Robson 2001). Particles of diameter greater than 10 µ fail to reach the bronchioles.…”

mentioning

confidence: 99%

“…Problems with this method have been previously outlined (Whittle, Guy, and Robson 2001). In essence, they include the lipophilic nature of cannabis components, the need for carrier molecules or other facilitators of transdermal absorption, and results to date that approximate only 10% of necessary serum levels (Challapalli and Stinchcomb 2002).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Introduction: Cannabis: From Pariah to Prescription

Russo

2004

Journal of Cannabis Therapeutics

View full text Add to dashboard Cite

SUMMARY.Cannabis has been employed in human medicine for more than 4000 years. In the last century, political prohibition led to its disappearance from the conventional pharmacopoeia, but this trend is reversing due to the broad acceptance and application of this forbidden medicine by patients with chronic and intractable disorders inadequately treated by available therapeutics. This study addresses the "road back" for cannabis medicines, and reacceptance as prescription products.Current pharmacology of the two primary therapeutic phytocannabinoids, THC and CBD, is reviewed with respect to herbal synergy and as pertains to treatment of pain, spasm and the wide range of therapeutic applications and adverse effects of cannabis.In particular, the efforts of GW Pharmaceuticals to develop cannabis based medicine extracts (CBME) are documented including cultivation of genetically-selected medical-grade cannabis cloned strains in glass houses with organic and integrated pest management techniques, and their processing employing supercritical carbon dioxide extraction and winterization. These CBMEs are then available for formulation of dosEthan Russo, MD, is a Clinical Child and Adult Neurologist,

show abstract

“…As previously published two years ago (Whittle, Guy, and Robson 2001), many hurdles exist when considering the concept of how to produce a prescription cannabis product (p. 186):…”

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations